Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report […]

Related Keywords

,Oncternal Therapeutics Company Profile ,Richmond Brothers Inc ,Pasadena Private Wealth ,Renaissance Technologies ,Millennium Management ,Oncternal Therapeutics Inc ,Vanguard Group Inc ,Oncternal Therapeutics ,Free Report ,Get Free Report ,Director Robert James Wills ,Private Wealth ,Orphan Receptor ,Oncternal Therapeutics Daily ,Nasdaq Onct ,Conct ,Medical ,Initiated Coverage ,Stocknews Com ,